LV systolic impairment in patients with asymptomatic coronary heart disease and type 1 diabetes is related to coronary atherosclerosis, glycaemic control and advanced glycation endproducts

Eur J Heart Fail. 2007 Oct;9(10):1044-50. doi: 10.1016/j.ejheart.2007.07.013. Epub 2007 Aug 24.

Abstract

Aims: To evaluate whether heart failure in type 1 diabetes is linked to poor glycaemic control, coronary atherosclerosis or advanced glycation endproducts (AGEs).

Methods: Twenty six patients with type 1 diabetes (mean duration 32+/-5 years), and 16 age matched controls were recruited. Mean HbA(1c) through 18 years (HbA(1c)18), serum levels of AGEs and coronary atherosclerotic burden (CAB) were determined by IVUS. Peak tissue velocities and strain by tissue Doppler imaging were measured in 12 LV regions as an evaluation of LV function.

Results: Systolic tissue velocity was inversely correlated to CAB (r=0.53, p<0.01), to HbA(1c)18 (r=0.46, p<0.05) and to the duration of diabetes (r=0.46, p<0.05). Systolic strain was inversely correlated to HbA(1c)18 (r=0.45, p<0.05), to duration of diabetes (r=0.41, p<0.05), and tended to correlate with AGEs (r=0.37, p=0.07). In multiple regression analyses, CAB and HbA(1c)18 were significant independent predictors for systolic velocity, while AGEs and duration of diabetes were significant predictors of systolic strain.

Conclusion: LV systolic function was impaired by increasing coronary atherosclerosis and worsening of glycaemic control. AGEs might be another mechanism for the increased risk of heart failure in type 1 diabetes.

MeSH terms

  • Adult
  • Case-Control Studies
  • Coronary Artery Disease / diagnostic imaging
  • Coronary Artery Disease / physiopathology*
  • Diabetes Mellitus, Type 1 / diagnostic imaging
  • Diabetes Mellitus, Type 1 / physiopathology*
  • Disease Progression
  • Female
  • Glycated Hemoglobin*
  • Glycation End Products, Advanced*
  • Heart Failure / physiopathology
  • Heart Ventricles / diagnostic imaging
  • Heart Ventricles / pathology*
  • Humans
  • Hyperglycemia / prevention & control*
  • Male
  • Middle Aged
  • Risk Factors
  • Time Factors
  • Ultrasonography

Substances

  • Glycated Hemoglobin A
  • Glycation End Products, Advanced